The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy

R. A. Wilke; L. B. Ramsey; S. G. Johnson; W. D. Maxwell; H. L. McLeod; D. Voora; R. M. Krauss; D. M. Roden; Q. Feng; R. M. Cooper-Dehoff; L. Gong; T. E. Klein; M. Wadelius; M. Niemi

Journal ArticleOPEN ACCESS

The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy

Clinical Pharmacology and Therapeutics (2012) 92(1) 112-117

DOI: 10.1038/clpt.2012.57

278Citations

223Readers

Abstract

Cholesterol reduction from statin therapy has been one of the greatest public health successes in modern medicine. Simvastatin is among the most commonly used prescription medications. A non-synonymous coding single-nucleotide polymorphism (SNP), rs4149056, in SLCO1B1 markedly increases systemic exposure to simvastatin and the risk of muscle toxicity. This guideline explores the relationship between rs4149056 (c.521T

Cite

CITATION STYLE

APA

Wilke, R. A., Ramsey, L. B., Johnson, S. G., Maxwell, W. D., McLeod, H. L., Voora, D., … Niemi, M. (2012). The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clinical Pharmacology and Therapeutics, 92(1), 112–117. https://doi.org/10.1038/clpt.2012.57

The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy

Abstract

Cite

Register to see more suggestions